System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Pierre Sesques

Hematology — Hospices Civils de Lyon, France

LeadR Profile

Pierre Sesques Hospices Civils de Lyon France
596 ScienceLeadR Reputation 596

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Short Biography

·        Pierre Sesques  is an MD in the Hematology Department at Hospices Civils de Lyon in Lyon.

He is specialized in hematologic malignancies, in particular non-Hodgkin and Hodgkin lymphomas. He obtained his master degree in “Therapeutic Innovations in Oncology” from the Claude Bernard University of Lyon in 2015. In 2017, he continued his university studies and graduated as a Doctor of Medicine.

He has been especially interested in the clinical and biological study of malignant lymphoma – major focuses of his work include the description and validation of prognostic factors as well as clinical trials in aggressive lymphomas, CART cells or bispecific antibodies. He has been involved as a coordinator or co-investigator in many clinical trials and studies within his field.

 

Organizations

Career arc: 2013 - 2026
Source: PubMed

Hospices Civils de Lyon

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 109

Citations

Citations: 1 989 1st author: 13 Last author: 8 Unique author: 0

Main journals

Blood 30
Blood Adv 11
Hematol Oncol 10
Hemasphere 7
Leuk Lymphoma 5

Best Journals

J Hematol Oncol 3
Cancer Cell 1
Lancet Haematol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Outcomes of ibrutinib plus lenalidomide combination in patients with large Bcell lymphoma refractory to or relapsing after CAR-T-cell therapy and who failed or were ineligible for bispecific antibodies: a multicenter real-world REALI-T study.
cells, hematology, antibodies, lymphoma, lenalidomide, therapeutics, t-lymphocytes, antibodies, bispecific, car-t cell		Haematologica20260
Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study.
cells, lymphoma, lymphoma, large b-cell, diffuse, positron emission tomography computed tomography, nuclear medicine, therapeutics, t-lymphocytes, car-t cell		Eur J Nucl Med Mol Imaging20260
Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era.
cells, hematology, lymphoma, b-cell, lymphoma, therapeutics, b-lymphocytes		Br J Haematol20260
Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party.
cells, lymphoma, lymphoma, mantle-cell		Bone Marrow Transplant20260
Hemophagocytic lymphohistiocytosis-like syndrome after CD19-directed CAR T-cells for B-cell lymphoma and B-cell acute lymphoblastic leukemia: A LYSA, SFCE, and GRAALL study from the DESCAR-T registry.
registries, cells, mortality, precursor cell lymphoblastic leukemia-lymphoma, lymphoma, b-cell, lymphoma, adrenal cortex hormones, leukemia, therapeutics, l-lactate dehydrogenase, lymphohistiocytosis, hemophagocytic, b-lymphocytes, car-t cell		Hemasphere20260

Clinical Studies 8

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Director: 1

By phase:

N/A 4
Phase 2 2
Phase 1/Phase 2 1
Phase 3 1

By status:

Active not recruiting 2
Completed 2
Recruiting 2
Not yet recruiting 1
Unknown 1

By type:

Interventional 5
Observational 3

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 1
multicentric5to9 0
multicentricup10 6

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Proof of Concept for Real time Multicentric Monitoring of MRD by PET and ctDNA in Aggressive B Cell Lymphomas
NCT07514715 — cells, blood, circulating tumor dna, lymphoma, b-cell, lymphoma, positron-emission tomography, neoplasms, neoplasm, residual, therapeutics, hematologic tests, dna, b-lymphocytes		N/ANot yet recruiting2026
Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients
NCT05735834 — lymphoma, solutions, capsules, rituximab, therapeutics		Phase 3Active not recruiting2024
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide Doxorubicin Vincristine and Prednisone (CHOP) in Circulating Tumor (ct)DNA High Risk Patients With Untreated Diffuse Large B Cell Lymphoma
NCT04980222 — cytokines, cells, body surface area, prednisolone, safety, prednisone, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, cyclophosphamide, doxorubicin, neoplasms, cytokine release syndrome, rituximab, vincristine, therapeutics, b-lymphocytes		Phase 2Active not recruiting2022
Circulating Tumor DNA in Primary Mediastinal Large B cell Lymphoma (PMBL)
NCT04824950 — cells, high-throughput nucleotide sequencing, circulating tumor dna, lymphoma, b-cell, lymphoma, neoplasms, drug therapy, dna, b-lymphocytes, chemotherapy		N/ARecruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS